Virios Therapeutics, Inc. (NASDAQ:VIRI) Short Interest Up 70.1% in June

Virios Therapeutics, Inc. (NASDAQ:VIRI) was the target of a large growth in short interest in June. As of June 15th, there was short interest totalling 570,300 shares, a growth of 70.1% from the May 31st total of 335,300 shares. Based on an average daily volume of 1,150,000 shares, the days-to-cover ratio is presently 0.5 days.

Analyst Upgrades and Downgrades

Separately, Maxim Group started coverage on shares of Virios Therapeutics in a report on Thursday, June 20th. They issued a “buy” rating and a $1.00 price target for the company.

Virios Therapeutics Price Performance

NASDAQ VIRI traded down $0.02 during trading hours on Friday, reaching $0.22. The company’s stock had a trading volume of 938,482 shares, compared to its average volume of 2,136,266. Virios Therapeutics has a fifty-two week low of $0.16 and a fifty-two week high of $2.42. The company’s 50-day moving average is $0.30 and its two-hundred day moving average is $0.42.

Virios Therapeutics (NASDAQ:VIRI) last issued its quarterly earnings data on Thursday, May 9th. The company reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.01. As a group, research analysts forecast that Virios Therapeutics will post -0.27 earnings per share for the current fiscal year.

About Virios Therapeutics

Virios Therapeutics, Inc, a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia.